Literature DB >> 9814870

Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City.

J E Sackoff1, L V Torian, T R Frieden, K F Brudney, I B Menzies.   

Abstract

OBJECTIVE: To determine whether Centers for Disease Control and Prevention recommendations for purified protein derivative (PPD) testing and tuberculosis (TB) preventive therapy for PPD-positive patients are implemented in HIV clinics.
DESIGN: Retrospective medical chart review.
SETTING: Ten hospital-based HIV clinics in New York City. PARTICIPANTS: A total of 2397 patients with a first clinic visit in 1995. OUTCOME MEASURES: PPD testing of eligible patients, and recommendation of preventive therapy and completion of regimen in PPD-positive patients.
METHOD: Outpatient medical records were abstracted for TB history, PPD testing, TB preventive therapy, and patient demographic, social and clinical characteristics. Multivariate analyses were performed using logistic regression.
RESULTS: Of 1342 patients with an indication for a PPD test, 865 (64%) were PPD tested in the clinic and 757 (88%) returned to have it read. Factors strongly associated with PPD testing in the clinic were number of visits, same sex behavior with men, and CD4+ lymphocyte count above 200 x 10(6)/l. Preventive therapy was recommended for 80% of newly identified PPD-positive patients and 22% of previously identified PPD-positive patients. Of 119 patients on preventive therapy in the clinic, 49 (41%) completed the regimen, 50 (42%) were lost to follow-up, and 20 (17%) discontinued therapy or their status could not be determined.
CONCLUSION: A significant number of missed opportunities to implement TB prevention practices were identified in HIV clinics. Focused attention in HIV clinics, and increased collaboration between HIV clinics and TB control programs may be needed to increase adherence to prevention guidelines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814870     DOI: 10.1097/00002030-199815000-00013

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

Review 1.  Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons.

Authors:  Christopher Akolo; Florence Bada; Evaezi Okpokoro; Ogochukwu Nwanne; Sharon Iziduh; Eno Usoroh; Taofeekat Ali; Vivian Ibeziako; Olanrewaju Oladimeji; Michael Odo
Journal:  World J Virol       Date:  2015-05-12

2.  Zip code-level risk factors for tuberculosis: neighborhood environment and residential segregation in New Jersey, 1985-1992.

Authors:  D Acevedo-Garcia
Journal:  Am J Public Health       Date:  2001-05       Impact factor: 9.308

3.  Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre.

Authors:  Paul Brassard; Travis Salway Hottes; Richard G Lalonde; Marina B Klein
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

4.  Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain.

Authors:  Asuncion Diaz; Mercedes Diez; Maria Jose Bleda; Mikel Aldamiz; Miguel Camafort; Xabier Camino; Concepcion Cepeda; Asuncion Costa; Oscar Ferrero; Paloma Geijo; Jose Antonio Iribarren; Santiago Moreno; Maria Elena Moreno; Pablo Labarga; Javier Pinilla; Joseba Portu; Federico Pulido; Carmen Rosa; Juan Miguel Santamaría; Mauricio Telenti; Luis Trapiella; Monica Trastoy; Pompeyo Viciana
Journal:  BMC Infect Dis       Date:  2010-09-14       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.